CJC-1295 Side Effects

Known side effects

The following side effects have been reported in research studies and user reports for CJC-1295:

• Injection site reactions: redness, swelling, or itching at the injection site. Very common, especially in the first few weeks. Rotate injection sites to minimize.
• Flushing and warmth: facial and upper body flushing shortly after injection, similar to a niacin flush. Nearly universal in early use, typically subsides within 30-60 minutes and diminishes over weeks.
• Water retention: puffiness in face, hands, and feet, particularly in the morning. Common and usually dose-dependent. May require sodium reduction and adequate hydration to manage.
• Headache: mild to moderate headaches, most common during the first 1-2 weeks. Usually transient and resolves without intervention.
• Increased appetite: more commonly reported when stacked with ipamorelin, which activates the ghrelin pathway. Can complicate caloric deficit goals.
• Dizziness and lightheadedness: occasional, typically shortly after injection. More common with higher doses.
• Nausea: mild nausea reported occasionally, usually in the first week. Taking on an empty stomach as recommended may exacerbate this.
• Numbness and tingling in hands: carpal tunnel-like symptoms from fluid retention causing soft tissue swelling. Usually dose-dependent and resolves with dose reduction.
• Vivid dreams: frequently reported, generally considered a sign of enhanced REM sleep rather than a concerning side effect.
• Joint stiffness: occasional reports, more common with the DAC version due to sustained GH elevation. May indicate dose is too high.
• Blood sugar elevation: GH can decrease insulin sensitivity. Monitoring recommended for pre-diabetic or insulin-resistant individuals (PMID: 28400207). More concerning with DAC version due to sustained GH levels.
• Cardiac concerns: FDA flagged heart-related side effects during PCAC review. Transient increased heart rate reported in community use. The Phase II DAC trial was halted after a participant death, though causation was not confirmed.
• Immunogenicity: potential for antibody development with repeated use. FDA flagged this as a concern during the Category 2 review process. Limited long-term data available.

Severity and frequency

Limited clinical data is available for CJC-1295. Side effect frequency and severity are based on available research and anecdotal reports. More data is needed for definitive safety profiles.

When to seek medical attention

Contact your healthcare provider immediately if you experience:

• Severe or persistent symptoms that do not improve
• Signs of an allergic reaction (rash, swelling, difficulty breathing)
• Severe abdominal pain
• Changes in vision or neurological symptoms
• Any symptom that concerns you

Risk factors

Side effect risk may be higher in certain populations. Discuss your complete medical history with your doctor, including:

• Pre-existing medical conditions
• Current medications (drug interactions)
• Pregnancy or plans to become pregnant
• History of allergic reactions to peptides or similar compounds
• Note: CJC-1295 is a research compound without established human safety data from FDA-approved clinical trials

Research references

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — Journal of Clinical Endocrinology & Metabolism (2006) [PubMed]
• Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog — Journal of Clinical Endocrinology & Metabolism (2006) [PubMed]
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects — Growth Hormone & IGF Research (2009) [PubMed]
• Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog — Endocrinology (2005) [PubMed]
• Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse — American Journal of Physiology — Endocrinology and Metabolism (2006) [PubMed]
• Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men — Journal of Clinical Endocrinology & Metabolism (1992) [PubMed]
• Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women — Journal of Clinical Endocrinology & Metabolism (1997) [PubMed]
• The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV — Journal of Frailty and Aging (2019) [PubMed]
• Ipamorelin, the first selective growth hormone secretagogue — European Journal of Endocrinology (1998) [PubMed]
• The safety and efficacy of growth hormone secretagogues — Sexual Medicine Reviews (2018) [PubMed]
• Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males — Translational Andrology and Urology (2020) [PubMed]
• Sleep-promoting effects of growth hormone-releasing hormone in normal men — American Journal of Physiology (1993) [PubMed]
• Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Testing and Analysis (2021) [PubMed]
• Chemical modification of Class II G-protein coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies — Pharmacology & Therapeutics (2010) [PubMed]